The Allowed Claims include Composition of FT-104, which is a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice…


Previous articleAwakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Next articleMYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia